ACF Equity Research

ACF was set up to improve the effectiveness of capital markets for smaller and mid-sized companies. The majority of jobs are created by smaller companies not global companies. If we can help improve companies use of capital markets more projects will be completed, more jobs created, more global GDP grown, which in turn helps create more resources for education, leading to equality and opportunity for those who are still oppressed by ignorance and poverty.

ACF Equity Research is an independent research house specialising in the highest specification independent equity research for corporate clients.

We deliver premium independent corporate sponsored equity research characterised by its accuracy, clarity and foresight based upon a fundamental valuation approach.

Our independent research is designed to educate our professional investor readers about your company, with an emphasis on clear and accurate explanations. Our mission is to improve company’s liquidity through credible equity research services, excellent international distribution and reliable access for investment managers.

We believe in the importance and value of clarity, the careful articulation of technical ideas, concepts and solutions.

Our team of analysts are independently minded individuals who believe in thoroughness, technical competence and clear punchy communications.

Accuracy | Clarity | Foresight

Coeptis Therapeutics Inc. (COEP) Initiation Note ACF Equity Research 16112022

Coeptistx (COEP) Deverra Deal Flash Note 20042023

Coeptis Therapeutics Inc. (COEP) YE22 1Q23 & DeSPAC 29062023

Research from ACF Equity Research, ACF Equity Research

Research from ACF Equity Research

Equity Bottom-Up

Coeptis Therapeutics Holdings / Equity Bottom-Up

<ul>
<li>Deverra deal adds two patented assets to COEP product pipeline;</li>
<li>Reduces COEP risk profile and so contributes to our valuation range;</li>
<li>DVX201 - Unmodified NKC therapy from pooled donor CD34+ cells.</li>
</ul>


Deverra deal adds two patented assets to COEP product pipeline;
Reduces COEP risk profile and so contributes to our valuation range;
DVX201 - Unmodified NKC therapy from pooled donor CD34+ cells.


Coeptistx (COEP) Deverra Deal Flash Note 21082023